Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Osteoarthritis
Interventions: Celecoxib, Any commercially available NSAID with the indication for osteoarthritis; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 55 Years to 99 Years
Enrollment: 8,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 750
States / cities: Abbeville, Alabama • Alexander City, Alabama • Bay Minette, Alabama + 603 more

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions: Not listed
Lead sponsor: OvaGene Oncology, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Bronchial Aspiration
Interventions: Bed Head elevation, H2 blockers and mouth wash, Data collection for comparison; Other
Lead sponsor: Marshall University; Other
Eligibility: 18 Years and older
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions: Nicotinamide, Standard Glaucoma Therapy; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid Use Disorder, Pregnancy Related, Substance Use, Drug Abuse, Drug Abuse in Pregnancy, Drug Addiction
Interventions: Personally-Tailored Opioid-overdose and Medication for opioid use disorder (MOUD) Education (TOME), Control; Behavioral
Lead sponsor: T. John Winhusen, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 6
States / cities: Jacksonville, Florida • Pittsburgh, Pennsylvania • Charleston, South Carolina + 3 more

Conditions: PTSD, MDD
Interventions: PE/Pramipexole; Combination Product
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Hydrocephalus
Interventions: Rhaeos Shunt Monitoring System; Device
Lead sponsor: Rhaeos, Inc.; Industry
Eligibility: Not listed
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: Nausea, Vomiting, Abdominal Pain
Interventions: esomeprazole (PPI); Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer
Interventions: Degarelix, Leuprolide; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: Male only
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 48
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 42 more

Conditions: Heart Disease, Ischemic, Ischemia, Myocardial, Ischemic Heart Disease, Unstable Angina
Interventions: Not listed
Lead sponsor: Inverness Medical Innovations; Industry
Eligibility: 21 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Boston, Massachusetts • Lebanon, New Hampshire • Cleveland, Ohio + 1 more

Conditions: Healthy
Interventions: Dexcom continuous glucose monitor, Fitbit activity tracker, Subjects record daily activity, Subjects record psychological state; Device · Behavioral
Lead sponsor: Savvysherpa, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Minnetonka, Minnesota

Conditions: Primary Health Care
Interventions: Salud al Día; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Dementia, Healthy
Interventions: Project Grace; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 40 Years and older
Enrollment: 21,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Liver Diseases, Liver Fibrosis, Liver Cirrhosis, NASH Fibrosis, Decompensated Non-Alcoholic Steatohepatitis Cirrhosis, Orthotopic Liver Transplantation
Interventions: Ultrasound; Diagnostic Test
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Rialto, California • Tulsa, Oklahoma • Germantown, Tennessee

Conditions: Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 4
States / cities: Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more

Conditions: Memory Replay, HippoCamera
Interventions: Memory replay; Behavioral
Lead sponsor: Boston College; Other
Eligibility: 15 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Stress, Mindfulness, Early Life Adversity
Interventions: Mindfulness, Coping; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 29 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 4,401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 152
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more

Conditions: Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
Interventions: Lenvatinib, ABBV-324; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 7 more

Conditions: Sepsis
Interventions: Conservative Fluid Management Strategy; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cerebral Autoregulation Impairment, Postoperative Cognitive Dysfunction, Postoperative Delirium
Interventions: BrainProtect System, Standard perioperative management; Device · Procedure
Lead sponsor: Scienceforbrain, UAB; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cervical Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions: Psychosocial Telephone Counseling (PTC); Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Irvine, California

Conditions: Metastatic Castration Sensitive Prostate Cancer
Interventions: Degarelix, Ipilimumab, Radical Prostatectomy; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

GI-Reasons- A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)

DNA Single Nucleotide Polymorphisms as Predictors of Toxicity

Prevention of Broncho-aspiration (BA) in Adult Subjects During Their ICU Stay

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

Personally-Tailored Opioid-overdose and Medication for Opioid Use Disorder (MOUD) Education (TOME) for Pregnant and Postpartum Persons in MOUD

Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression

Flow Detection in Open and Closed Shunt Valve Periods

The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep

A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease

The Ischemia Modified Albumin In Diagnosing Ischemic New Events

Data Acquisition to Model Glycemic Response

Salud al Día: Engaging Latino Parents in Pediatric Primary Care

Encouraging Cognitive Screenings at African American Churches

Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

A VIRTUAL Three-month Intervention Study of the Effects of a Smartphone Application (HippoCamera) on Memory in Teens and Young Adults With Down Syndrome

Remote Mindfulness Training Following Early Life Adversity

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)

BrainProtect-guided, Real-time Cerebral Autoregulation Monitoring and Protection of Brain During Cardiac Surgery With Cardiopulmonary Bypass Requiring Heart-lung Machine

Telephone Counseling or Standard Care in Patients Who Have Completed Treatment for Stages I, II, or III Cervical Cancer

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy